• Jacobio dosed the first China patient in a Phase Ib/III study of pan-KRAS inhibitor JAB-23E73 with nab-paclitaxel, gemcitabine as first-line therapy for KRAS-mutant pancreatic cancer.
• Early findings were already presented in its 2025 annual report; updated trial results will be generated as the new study progresses.
• Preliminary Phase I readouts showed manageable safety and signs of tumor shrinkage in heavily pretreated solid-tumor patients, supporting expansion into first-line pancreatic cancer.
• AstraZeneca holds ex-China rights; the partners plan joint development and co-commercialization in mainland China, sharpening Jacobio’s near-term strategic focus.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobio Pharmaceuticals Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260720-12249018), on July 19, 2026, and is solely responsible for the information contained therein.